What should be monitored when a patient is receiving cyclosporine?

Monitoring for signs of nephrotoxicity is critical when a patient is receiving cyclosporine because this medication is well-known to have potential adverse effects on kidney function. Cyclosporine can cause damage to the kidneys, leading to increased serum creatinine levels and decreased urine output, which are signs of nephrotoxicity. Regular monitoring of renal function through serum creatinine, blood urea nitrogen (BUN), and urine output is essential to identify any renal impairment early and manage it appropriately.

In contrast, while dehydration, anemia, and hyperthermia are important clinical considerations in patient care, they are not the primary concerns specifically associated with cyclosporine therapy. The focus on nephrotoxicity emerges from the known pharmacological effects of cyclosporine and the need for vigilant monitoring to prevent significant complications related to renal function.